PILOT STUDY OF THE CORRELATION BETWEEN THE FINDINGS OF ATYPICAL/MALIGNANT CELLS IN SPUTUM AND FLUORESCENCE BRONCHOSCOPY IN PATIENTS AT RISK FOR LUNG CANCER OF THE LIFE IMAGING SYSTEM AND WHITE LIGHT BRONCHOSCOPY
- Evaluate the efficacy of autofluorescence bronchoscopy using the Lung Imaging
Fluorescence Endoscopic System with conventional white-light bronchoscopy for the early
detection of lung cancer in selected patients with known or suspected bronchogenic
carcinoma, completely resected head and neck cancer, and successfully treated
early-stage lung cancer.
- Determine the number of areas of moderate dysplasia, severe dysplasia, and carcinoma in
situ in patients treated with surgery for lung cancer compared with patients treated
with combined modality therapy.
- Determine the ability of immunohistochemistry to predict whether lesions of moderate to
severe dysplasia will progress to cancer.
OUTLINE: If possible, patients produce a 3-day pooled sputum sample prior to bronchoscopy.
Patients then undergo tracheobronchial white-light bronchoscopy followed by autofluorescence
bronchoscopy using the Lung Imaging Fluorescence Endoscopic (LIFE) Device attached to a
computerized video camera. Visualized tissue is classified as either normal, abnormal, or
suspicious. Abnormal or suspicious tissue is biopsied, as is tissue from 1 or 2 randomly
chosen normal sites. Immunohistochemical analysis of the biopsy material is conducted
without knowledge of the bronchoscopic results. Patients unable to produce a sputum sample
prior to bronchoscopy are required to do so after bronchoscopy.
PROJECTED ACCRUAL: A total of 70 patients will be entered.
Primary Purpose: Screening
J. Michael Hamilton, MD
National Cancer Institute (NCI)
United States: Federal Government
|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support||Bethesda, Maryland 20892-1182|